Patents by Inventor Richard E. Donaldson

Richard E. Donaldson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Process for the preparation of ribonucleotide reductase inhibitors
    Patent number: 5760210
    Abstract: The present invention is directed toward a novel process of preparing 2'-exocyclic vinylfluoride derivatives of cytidine analogues for use as ribonucleotide reductase inhibitors.
    Type: Grant
    Filed: July 30, 1996
    Date of Patent: June 2, 1998
    Assignee: Merrell Pharmaceuticals Inc.
    Inventors: James R. McCarthy, Donald P. Matthews, Jeffrey S. Sabol, James R. McConnell, Richard E. Donaldson, Robert Duguid
  • Process for the preparation of ribonucleotide reductase inhibitors
    Patent number: 5589587
    Abstract: The present invention is directed toward a novel process of preparing 2'-exocyclic vinylfluoride derivatives of cytidine analogues for use as ribonucleotide reductase inhibitors. The novel process of the present invention utilizes a cytidine derivative as the required starting material and provides the ribonucleotide reductase inhibitor in a more efficient than the reaction sequence. The process is more efficient than the process disclosed by McCarthy et al. in European Patent Application Publication No. 0 372 268 published Jun. 13, 1990, in that it requires fewer chromatographies and results in an overall yield of greater than 25% for the five steps. The present invention further provides the ribonucleotide reductase inhibitor in a four step reaction sequence and results in an overall yield of greater than 35%.
    Type: Grant
    Filed: April 10, 1995
    Date of Patent: December 31, 1996
    Assignee: Merrell Pharmaceuticals Inc.
    Inventors: James R. McCarthy, Donald P. Matthews, Jeffrey S. Sabol, James R. McConnell, Richard E. Donaldson, Robert Duquid
  • Process for the preparation of ribonucleotide reductase inhibitors
    Patent number: 5508393
    Abstract: The present invention is directed toward a novel process of preparing 2'-exocyclic vinylfluoride derivatives of cytidine analogues for use as ribonucleotide reductase inhibitors. The novel process of the present invention utilizes a cytidine derivative as the required starting material and provides the ribonucleotide reductase inhibitor in a more efficient five step reaction sequence. The present invention further provides the ribonucleotide reductase inhibitor in a four step reaction sequence and results in an overall yield of greater than 35%.
    Type: Grant
    Filed: May 11, 1995
    Date of Patent: April 16, 1996
    Assignee: Hoeschst Marion Roussel, Inc.
    Inventors: James R. McCarthy, Donald P. Matthews, Jeffrey S. Sabol, James R. McConnell, Richard E. Donaldson, Robert Duquid
  • Medroxalol intermediates
    Patent number: 4701541
    Abstract: The compounds 1-(3,4-methylenedioxyphenyl)-3-(N-benzylamino)butane and methyl 5-[[4-(3,4-methylenedioxyphenyl)-N-benzyl-2-butylamino]acetyl]salicylate are intermediates in the preparation of medroxalol.
    Type: Grant
    Filed: November 24, 1986
    Date of Patent: October 20, 1987
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Richard E. Donaldson, John F. Hoops
  • Medroxalol intermediates
    Patent number: 4697024
    Abstract: The compounds 1-(3,4-methylenedioxyphenyl)-3-(N-benzylamino)butane and methyl 5-[[4-(3,4-methylenedioxyphenyl)-N-benzyl-2-butylamino]acetyl]salicylate are intermediates in the preparation of medroxalol.
    Type: Grant
    Filed: November 24, 1986
    Date of Patent: September 29, 1987
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Richard E. Donaldson, John F. Hoops